

Clinical effectiveness and safety of pooled, random donor platelet concentrates, leukoreduced and stored up to seven days either in additive solution with and without pathogen reduction or plasma in haemato-oncological patients

Submission date 08/02/2007	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 08/02/2007	Overall study status Completed	☐ Protocol
Last Edited 02/09/2008	Condition category Haematological Disorders	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr J L H Kerkhoffs

Contact details
HagaHospital
Leyweg 275
Den Haag
Netherlands
2545 CH
+31 (0)70 359 2004
J.Kerkhoffs@hagaziekenhuis.nl

Additional identifiers

Protocol serial number
HO82; NTR861

Study information

Scientific Title

Acronym

HOVON 82

Study objectives

Platelet additive solution platelet concentrates (PAS III-PC) and pathogen reduced (PR)-PAS III-PC are non-inferior compared to plasma platelet concentrates (Plasma-PC) in terms of recovery, estimated by the one-hour corrected count increments (CCI) post-transfusion.

Secondary objectives:

1. To assess the effectiveness in relation to storage time of the used platelet product
2. To evaluate whether clinical factors interact with the different study products leading to a difference in platelet refractoriness
3. To assess the 24-hour CCI
4. To assess the safety (bleeding complications and adverse transfusion reactions)
5. To assess transfusion requirement (red cells and platelets)
6. To assess the transfusion interval

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the local ethics committee (METC Zuidwest Holland) on the 22nd January 2007 (ref: METC protocol-nr 06-094) (ref. of approval letter: 2007-054).

Study design

Randomised, active-controlled, parallel group multicentre trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Thrombocytopenia

Interventions

All patients will be randomised to receive one of three platelet products during one transfusion period:

Arm A: plasma stored platelet concentrates (Plasma-PC)

Arm B: PAS III stored platelet concentrates (PAS III-PC)

Arm C: pathogen reduced PAS III stored platelet concentrates (PR-PAS III-PC)

Duration of study will be one transfusion period, which is defined as a period of six weeks or a maximum of five transfusions.

Intervention Type

Other

Phase

Phase III

Primary outcome(s)

One-hour CCI.

Key secondary outcome(s)

1. 24 hour CCI
2. Bleeding grade minimal two (Common Terminology Criteria for Adverse Events version three [CTCAE v 3.0])
3. Transfusion requirement, red cells and platelets
4. Platelet transfusion interval
5. Adverse transfusion reactions

Completion date

01/02/2008

Eligibility**Key inclusion criteria**

1. Age minimal 18 years
2. Expected minimal two platelet transfusion requirements
3. Written informed consent
4. Having a haemato-oncological disease

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Not Specified

Key exclusion criteria

1. Known immunological refractoriness to platelet transfusions, i.e. human leukocyte antigen (HLA)- and/or human platelet antigen (HPA)-alloimmunisation and/or clinical relevant auto-antibodies
2. Pregnancy (or lactating)
3. Previous inclusion in this study

Date of first enrolment

01/02/2007

Date of final enrolment

01/02/2008

Locations

Countries of recruitment

Netherlands

Study participating centre

HagaHospital

Den Haag

Netherlands

2545 CH

Sponsor information

Organisation

Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands)

ROR

<https://ror.org/056kpx27>

Funder(s)

Funder type

Research organisation

Funder Name

Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands)

Funder Name

The Sanquin Blood Supply Foundation (Stichting Sanquin Bloedvoorziening) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes